FIT Biotech Oy                                                            

Company release 20.8.2018 at 10:00 AM EET

Correction to company release dated August 16th, 2018: Chairman of the board on leave of absence

On the company release on August 16, 2018 there was an incorrect information about Rabbe Slätis' decision to leave the position as the Chairman of the Board temporarily and Chitra Bharucha's role as a vice chairman.

Correction: FIT Biotech's ("FIT Biotech", FITBIO: FN Finland) chairman of the board Rabbe Slätis has resigned from the position as the Chairman of the Board but will nonetheless remain as an ordinary member of the Board. Dr. Chitra Bharucha has been nominated as the new Chairman of the Board starting 16th of August 2018.

 

FIT Biotech OY
Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media